Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel:	Melanoma Management
Personen und Körperschaften:	Mohr, Peter, Kiecker, Felix, Soriano, Virtudes, Dereure, Olivier, Mujika, Karmele, Saiag, Philippe, Utikal, Jochen, Koneru, Rama, Robert, Caroline, Cuadros, Florencia, Chacón, Matias, Villarroel, Rodrigo U, Najjar, Yana G, Kottschade, Lisa, Couselo, Eva M, Koruth, Roy, Guérin, Annie, Burne, Rebecca, Ionescu-Ittu, Raluca, Perrinjaquet, Maurice, Zager, Jonathan S
In:	Melanoma Management, 6, 2019, 4, S. MMT33
Format:	E-Article
Sprache:	Englisch
veröffentlicht:	Future Medicine Ltd
Schlagwörter:	Dermatology Oncology

Details
Zusammenfassung:	<jats:p> Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011–2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma. </jats:p>
Umfang:	MMT33
ISSN:	2045-0885 2045-0893
DOI:	10.2217/mmt-2019-0015